Welcome to Paid Research Studies




  • Condition:   HIV Positive
    Interventions:   Behavioral: Positive Health Check;   Behavioral: Standard of Care
    Sponsors:   RTI International;   Centers for Disease Control and Prevention
    Not yet recruiting

  • Condition:   HIV/AIDS
    Intervention:   Behavioral: WELL Program
    Sponsors:   Louisiana State University Health Sciences Center in New Orleans;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting

  • Condition:   Human Immunodeficiency Virus
    Intervention:   Drug: Antiretrovirals
    Sponsors:   University of California, Los Angeles;   Los Angeles LGBT Center;   Tulane University
    Recruiting

  • Conditions:   HIV;   Mental Health;   Substance Use;   STI
    Interventions:   Behavioral: Automated Messaging & Monitoring;   Behavioral: Peer Support;   Behavioral: Coaching
    Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Tulane University Health Sciences Center;   University of California, San Francisco;   Friends Research Institute, Inc.
    Recruiting

  • Conditions:   HIV;   Mental Health;   Illicit Substance Use;   Sexually Transmitted Infections (STI)
    Interventions:   Behavioral: Level 1;   Behavioral: Level 2;   Behavioral: Level 3
    Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Wake Forest University Health Sciences;   Tulane University Health Sciences Center;   Columbia University
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: Cabotegravir tablets;   Drug: TDF/FTC tablets;   Drug: TDF/FTC placebo tablets;   Drug: CAB placebo tablets;   Drug: CAB LA;   Drug: Placebo for CAB LA
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   ViiV Healthcare;   Gilead Sciences
    Recruiting

  • Conditions:   AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HIV Infections;   Cardiovascular Diseases
    Interventions:   Drug: Pitavastatin;   Drug: Placebo
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
    Recruiting

  • Conditions:   Anal Cancer;   High-grade Squamous Intraepithelial Lesion;   HIV Infection;   Human Papilloma Virus Infection
    Interventions:   Drug: imiquimod;   Drug: fluorouracil;   Procedure: infrared photocoagulation therapy;   Procedure: thermal ablation therapy;   Procedure: laser therapy;   Other: clinical observation;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The EMMES Corporation;   University of Arkansas;   University of California, San Francisco
    Recruiting

  • Condition:   HIV/AIDS
    Intervention:  
    Sponsors:   Harvard School of Public Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Allergy and Infectious Diseases (NIAID);   NIH Office of AIDS Research (OAR);   National Institute of Mental Health (NIMH);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute on Deafness and Other Communication Disorders (NIDCD);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Dental and Craniofacial Research (NIDCR);   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   Tulane University School of Medicine
    Recruiting

  • Conditions:   Anal Intraepithelial Neoplasia;   High-grade Squamous Intraepithelial Lesion;   HIV Infection
    Interventions:   Drug: imiquimod;   Drug: fluorouracil;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The EMMES Corporation;   University of Arkansas
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   HIV Infection;   Metastatic Malignant Solid Neoplasm;   Recurrent Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   HIV Infections
    Intervention:   Drug: Raltegravir
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   AIDS-Related Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Stage II Hodgkin Lymphoma;   Stage IIA Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage III Hodgkin Lymphoma;   Stage IIIA Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IV Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vinblastine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anal Cancer;   Cervical Cancer;   Lung Cancer;   Lymphoma
    Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The EMMES Corporation;   AIDS and Cancer Specimen Resource;   University of Arkansas
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Antiretroviral Toxicity
    Intervention:  
    Sponsors:   Harvard School of Public Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Mental Health (NIMH);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute on Deafness and Other Communication Disorders (NIDCD);   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   National Institute of Neurological Disorders and Stroke (NINDS);   Tulane University School of Medicine;   National Institute of Dental and Craniofacial Research (NIDCR);   NIH Office of AIDS Research (OAR)
    Recruiting

  • Condition:   Human Immuno Deficiency (HIV) Infection
    Interventions:   Drug: Rilpivirine;   Drug: Zidovudine;   Drug: Abacavir;   Drug: Tenofovir disoproxil fumarate;   Drug: Lamivudine;   Drug: Emtricitabine
    Sponsor:   Janssen Sciences Ireland UC
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting